Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

Abstract

Despite the success of the combination of venetoclax with the hypomethylating agents (HMA) decitabine or azacitidine in inducing remission in older, previously untreated patients with acute myeloid leukemia (AML), resistance - primary or secondary - still constitutes a significant roadblock in the quest to prolong the duration of response. Here we review the proposed and proven mechanisms of resistance to venetoclax monotherapy, HMA monotherapy, and the doublet of venetoclax and HMA for the treatment of AML. We approach the mechanisms of resistance to HMAs and venetoclax in the light of the agents’ mechanisms of action. We briefly describe potential therapeutic strategies to circumvent resistance to this promising combination, including alternative scheduling or the addition of other agents to the HMA and venetoclax backbone. Understanding the mechanisms of action and evolving resistance in AML remains a priority in order to maximize the benefit from novel drugs and combinations, identify new therapeutic targets, define potential prognostic markers, and avoid treatment failure.

Keywords

Venetoclax / hypomethylating agents / resistance / acute myeloid leukemia / azacitidine / decitabine

References

[1] Siegel RL,Jemal A.Cancer statistics, 2020..CA Cancer J Clin2020;70:7-30

[2] Löwenberg B,van Putten W.High-dose daunorubicin in older patients with acute myeloid leukemia..N Engl J Med2009;361:1235-48

[3] Prébet T,Reutenauer S.Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup..J Clin Oncol2009;27:4747-53

[4] Wahlin A,Golovleva I.Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia..Br J Haematol2001;115:25-33

[5] Farag SS,Mrózek K.Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461..Blood2006;108:63-73 PMCID:PMC1895823

[6] Grimwade D,Harrison G.The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial..Blood2001;98:1312-20

[7] Estey E.Acute myeloid leukemia and myelodysplastic syndromes in older patients..J Clin Oncol2007;25:1908-15

[8] Krug U,Berdel WE.The treatment of elderly patients with acute myeloid leukemia..Dtsch Arztebl Int2011;108:863-70 PMCID:PMC3258577

[9] Othus M,Petersdorf SH.Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy..Biol Blood Marrow Transplant2015;21:559-64 PMCID:PMC4386840

[10] Petersdorf SH,Slovak M.A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia..Blood2013;121:4854-60 PMCID:PMC3682338

[11] Grimwade D,Moorman AV.Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials..Blood2010;116:354-65

[12] Bullinger L,Döhner H.Genomics of acute myeloid leukemia diagnosis and pathways..J Clin Oncol2017;35:934-46

[13] Kantarjian H,O’Brien S.Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia..Blood2010;116:4422-9 PMCID:PMC4081299

[14] Kantarjian H,Cortes J.Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome..Cancer2006;106:1090-8

[15] DiNardo CD,de Botton S.Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML..N Engl J Med2018;378:2386-98

[16] Stein EM,Fathi AT.Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib..Blood2019;133:676-87 PMCID:PMC6384189

[17] Stone RM,Sanford BL.Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation..N Engl J Med2017;377:454-64 PMCID:PMC5754190

[18] Bose P,Cortes JE.Treatment of relapsed/refractory acute myeloid leukemia..Curr Treat Options Oncol2017;18:17

[19] DiNardo CD,Pullarkat V.Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia..Blood2019;133:7-17 PMCID:PMC6318429

[20] Wei AH,Hou JZ.Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II Study..J Clin Oncol2019;37:1277-84 PMCID:PMC6524989

[21] Quintás-Cardama A,Liu-Dumlao T.Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia..Blood2012;120:4840-5 PMCID:PMC3952725

[22] Dombret H,Butrym A.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts..Blood2015;126:291-9 PMCID:PMC4504945

[23] Cashen AF,O’Donnell MR.Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia..J Clin Oncol2010;28:556-61

[24] Kantarjian HM,Dmoszynska A.Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia..J Clin Oncol2012;30:2670-7 PMCID:PMC4874148

[25] Al-Ali HK,Junghanss C.Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study..Leuk Lymphoma2012;53:110-7

[26] Cidado J,Proia T.AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells..Clin Cancer Res2020;26:922-34

[27] Richard-Carpentier G.Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy..Ther Adv Hematol2019;10:2040620719882822 PMCID:PMC6811760

[28] DiNardo CD,Pullarkat V.Azacitidine and venetoclax in previously untreated acute myeloid leukemia..N Engl J Med2020;383:617-29

[29] Braun T,Renneville A.Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial..Blood2011;118:3824-31

[30] Pleyer L,Sperr WR.Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival..Leuk Res2014;38:475-83

[31] Sekeres MA,List AF.Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north american intergroup study SWOG S1117..J Clin Oncol2017;35:2745-53 PMCID:PMC5562170

[32] Fenaux P,Hellstrom-lindberg E.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study..Lancet Oncol2009;10:223-32 PMCID:PMC4086808

[33] DiNardo CD,Benton C.Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies..Am J Hematol2018;93:401-7

[34] Sorm F,Cihák A.5-Azacytidine, a new, highly effective cancerostatic..Experientia1964;20:202-3

[35] Gu X,Tomlinson B.Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network..Leukemia2020;

[36] Qin T,Si J,Issa JP.Mechanisms of resistance to 5-aza-2’-deoxycytidine in human cancer cell lines..Blood2009;113:659-67 PMCID:PMC2628372

[37] Hollenbach PW,Brady H.A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines..PLoS One2010;5:e9001 PMCID:PMC2814859

[38] Leone G,Zardo G,Nervi C.Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias..Curr Med Chem2008;15:1274-87 PMCID:PMC2764862

[39] Bird AP.Use of restriction enzymes to study eukaryotic DNA methylation..J Mol Biol1978;118:27-47

[40] McGhee JD.Specific DNA methylation sites in the vicinity of the chicken beta-globin genes..Nature1979;280:419-20

[41] Desrosiers RC,Fleckenstein B.Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines..Proc Natl Acad Sci U S A1979;76:3839-43 PMCID:PMC383930

[42] Constantinides PG,Jones PA.Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides..Dev Biol1978;66:57-71

[43] Taylor SM.Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine..Cell1979;17:771-9

[44] Constantinides PG,Gevers W.Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment..Nature1977;267:364-6

[45] Jones PA.Cellular differentiation, cytidine analogs and DNA methylation..Cell1980;20:85-93

[46] Veselý J.Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells..Pharmacol Therap1985;28:227-35

[47] Stresemann C.Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine..Int J Cancer2008;123:8-13

[48] Kuykendall JR.5-azacytidine and decitabine monotherapies of myelodysplastic disorders..Ann Pharmacother2005;39:1700-9

[49] Lee TT.Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells..Biochem Pharmacol1976;25:1737-42

[50] Lu LJ.Mechanism of 5-azacytidine-induced transfer rna cytosine-5-methyltransferase deficiency..Cancer Res1980;40:2701-5

[51] Schaefer M,Hanna K.Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines..Cancer Res2009;69:8127-32

[52] Taylor SM.Mechanism of action of eukaryotic DNA methyltransferase..J Mol Biol1982;162:679-92

[53] Santi DV,Garrett CE.Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine..Proc Natl Acad Sci U S A1984;81:6993-7 PMCID:PMC392062

[54] Christman JK,Acs G.Formation of highly stable complexes between 5-azacytosine-substituted DNA and specific non-histone nuclear proteins. Implications for 5-azacytidine-mediated effects on DNA methylation and gene expression..J Biol Chem1985;260:4059-68

[55] Ferguson AT,Spitzner JR.Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2’deoxycytidine-induced cytotoxicity in human breast cancer cells..J Biol Chem1997;272:32260-6

[56] Oka M,Hamazaki T,Chang LJ.De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2’-deoxycytidine..Oncogene2005;24:3091-9

[57] Copeland RA,Scott MP.Targeting epigenetic enzymes for drug discovery..Curr Opin Chem Biol2010;14:505-10

[58] Champion C,Sénamaud-Beaufort C.Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine..PLoS One2010;5:e12388 PMCID:PMC2927531

[59] Chen L,Chang W.Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase..Biochemistry1991;30:11018-25

[60] Wilson VL,Momparler RL.Inhibition of DNA methylation in l1210 leukemic cells by 5-aza-2’-deoxycytidine as a possible mechanism of chemotherapeutic action..Cancer Res1983;43:3493-6

[61] Bender CM,Jones PA.DNA methylation as a target for drug design..Pharm Res1998;15:175-87

[62] Muvarak NE,Xia L.Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer..Cancer Cell2016;30:637-50 PMCID:PMC5201166

[63] Jüttermann R,Jaenisch R.Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation..Proc Natl Acad Sci U S A1994;91:11797-801 PMCID:PMC45322

[64] Stingele J,Boulton SJ.Mechanisms of DNA-protein crosslink repair..Nat Rev Mol Cell Biol2017;18:563-73

[65] Veselý J,Sorm F.Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2’-deoxycytidine..Cancer Res1968;28:1995-2000

[66] Mortusewicz O,Walter J,Leonhardt H.Recruitment of DNA methyltransferase I to DNA repair sites..Proc Natl Acad Sci U S A2005;102:8905-9 PMCID:PMC1157029

[67] Vispé S,Davoine E.Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2’-deoxycytidine in human leukemic KG1 cells..Oncotarget2015;6:15265-82 PMCID:PMC4558150

[68] Stein EM,Pollyea DA.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia..Blood2017;130:722-31 PMCID:PMC5572791

[69] Savona MR,Amrein PC.An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study..Lancet Haematol2019;6:e194-203

[70] Garcia-Manero G,Steensma DP.Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study..Blood2020;136:674-83 PMCID:PMC7414597

[71] Roboz GJ,Selleslag D.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia..Future Oncol2016;12:293-302 PMCID:PMC5684733

[72] Wei AH,Pocock C.The quazar aml-001 maintenance trial: results of a phase iii international, randomized, double-blind, placebo-controlled study of cc-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (aml) in first remission.2019;American Society of Hematology Washington, DC

[73] Claus R.Epigenetic targets in hematopoietic malignancies..Oncogene2003;22:6489-96

[74] Momparler RL,Gyger M.Clinical trial on 5-AZA-2ʹ-deoxycytidine in patients with acute leukemia..Pharmacol Therap1985;30:277-86

[75] Rivard GE,Demers J.Phase I study on 5-aza-2ʹ-deoxycytidine in children with acute leukemia..Leuk Res1981;5:453-62

[76] Wijermans P,Verhoef G.Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients..J Clin Oncol2000;18:956-62

[77] Wijermans PW,Huijgens PC.Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome..Leukemia1997;11:1-5

[78] Kantarjian H,Rosenfeld CS.Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study..Cancer2006;106:1794-803

[79] Lübbert M,Baila L.Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group..J Clin Oncol2011;29:1987-96

[80] Silverman LR,Peterson BL.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B..J Clin Oncol2002;20:2429-40

[81] Karon M,Leimbrock S.5-azacytidine: a new active agent for the treatment of acute leukemia..Blood1973;42:359-65

[82] Saiki JH,Hewlett JS.Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a southwest oncology group study..Cancer1981;47:1739-42

[83] Fenaux P,Hellström-Lindberg E.Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia..J Clin Oncol2010;28:562-9

[84] Harris NL,Diebold J.The world health organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997..Hematol J2000;1:53-66

[85] Silverman LR,Peterson BL.Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B..J Clin Oncol2006;24:3895-903

[86] Pleyer L,Girschikofsky M.Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group..Ann Hematol2014;93:1825-38 PMCID:PMC4176957

[87] Thépot S,Seegers V.Azacitidine in untreated acute myeloid leukemia: a report on 149 patients..Am J Hematol2014;89:410-6

[88] Hummel-Eisenbeiss J,Hals PA.The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells..Mol Pharmacol2013;84:438-50

[89] Wu P,Weng J.The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome..Leuk Res2015;39:216-20

[90] Brueckner B,Markelova MR.Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy..Mol Cancer Ther2010;9:1256-64

[91] Camiener GW.Studies of the enzymatic deamination of cytosine arabinoside-I..Biochem Pharmacol1965;14:1405-16

[92] Zauri M,Thézénas ML.CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer..Nature2015;524:114-8 PMCID:PMC4866471

[93] Eliopoulos N,Momparler RL.Drug resistance to 5-aza-2’-deoxycytidine, 2’,2’-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells..Cancer Chemother Pharmacol1998;42:373-8

[94] Beauséjour CM,Momparler L,Momparler RL.Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene..Cancer Gene Ther2001;8:669-76

[95] Valencia A,Rossi A.Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine..Leukemia2014;28:621-8 PMCID:PMC3948159

[96] Qin T,El Ahdab S.Mechanisms of resistance to decitabine in the myelodysplastic syndrome..PLoS One2011;6:e23372 PMCID:PMC3157379

[97] Gruber E,Shortt J,Kats LM.Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia..Leukemia2020;34:3388-92

[98] Grant S,Gleyzer M.Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells..Leukemia Research1986;10:1139-46

[99] Grant S,Gleyzer M.Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis..Cancer Res1984;44:5505-10

[100] Itzykson R,Cluzeau T.Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias..Leukemia2011;25:1147-52

[101] Bejar R,Stevenson K.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients..Blood2014;124:2705-12 PMCID:PMC4208285

[102] Traina F,Elson P.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms..Leukemia2014;28:78-87

[103] Cedena MT,Santos-lozano A.Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes..Oncotarget2017;8:106948-61 PMCID:PMC5739787

[104] Coombs CC,Devlin SM.Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia..Haematologica2016;101:e457-60 PMCID:PMC5394875

[105] Ali A,Dal Bello R Jr.Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia..Leukemia2018;32:1856-60

[106] Treppendahl MB,Grønbæk K.Predicting response to epigenetic therapy..J Clin Invest2014;124:47-55 PMCID:PMC3871230

[107] Li LH,Buskirk HH.Cytotoxicity and mode of action of 5-azacytidine on l1210 leukemia..Cancer Res1970;30:2760-9

[108] Cheng JX,Li Y.RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia..Nat Commun2018;9:1163 PMCID:PMC5862959

[109] Earnshaw WC,Kaufmann SH.Mammalian caspases: structure, activation, substrates and functions during apoptosis..Ann Rev Biochem1999;68:383-424

[110] Taylor RC,Martin SJ.Apoptosis: controlled demolition at the cellular level..Nat Rev Mol Cell Biol2008;9:231-41

[111] Strasser A,Adams JM.Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases..EMBO J2011;30:3667-83 PMCID:PMC3173800

[112] Czabotar PE,Strasser A.Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy..Nat Rev Mol Cell Biol2014;15:49-63

[113] Moldoveanu T,Kriwacki RW.Many players in BCL-2 family affairs..Trends Biochem Sci2014;39:101-11 PMCID:PMC4005919

[114] Llambi F,Tait SW.A unified model of mammalian BCL-2 protein family interactions at the mitochondria..Mol Cell2011;44:517-31 PMCID:PMC3221787

[115] Andreeff M,Zhang X.Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid..Leukemia1999;13:1881-92

[116] Venditti A,Maurillo L.Combined analysis of bcl-2 and mdr1 proteins in 256 cases of acute myeloid leukemia..Haematologica2004;89:934-9

[117] Delbridge AR,Strasser A.Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies..Nat Rev Cancer2016;16:99-109

[118] Cory S,Colman PM.Targeting BCL-2-like Proteins to Kill Cancer Cells..Trends Cancer2016;2:443-60

[119] Singh R,Sarosiek K.Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins..Nat Rev Mol Cell Biol2019;20:175-93 PMCID:PMC7325303

[120] Merino D,Lessene G,Roberts AW.BH3-mimetic drugs: blazing the trail for new cancer medicines..Cancer Cell2018;34:879-91

[121] Tse C,Adickes J.Abt-263: a potent and orally bioavailable bcl-2 family inhibitor..Cancer Res2008;68:3421-8

[122] Stilgenbauer S,Schetelig J.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study..Lancet Oncol2016;17:768-78

[123] Wilson WH,Czuczman MS.Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity..Lancet Oncol2010;11:1149-59 PMCID:PMC3025495

[124] Roberts AW,Brown JR.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease..J Clin Oncol2012;30:488-96 PMCID:PMC4979082

[125] Mason KD,Fletcher JI.Programmed anuclear cell death delimits platelet life span..Cell2007;128:1173-86

[126] Souers AJ,Boghaert ER.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets..Nat Med2013;19:202-8

[127] Vogler M,Dyer MJ.ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets..Br J Haematol2013;163:139-42

[128] Roberts AW,Pagel JM.Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia..N Engl J Med2016;374:311-22 PMCID:PMC7107002

[129] Roberts AW.Targeting BCL2 With BH3 mimetics: basic science and clinical application of venetoclax in chronic lymphocytic leukemia and related B cell malignancies..Clin Pharmacol Ther2017;101:89-98 PMCID:PMC5657403

[130] Pham TD,Li J,Wallace DC.Cristae remodeling causes acidification detected by integrated graphene sensor during mitochondrial outer membrane permeabilization..Sci Rep2016;6:35907 PMCID:PMC5081517

[131] Lucantoni F,Llorente-Folch I.BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose..Oncotarget2018;9:26046-63 PMCID:PMC5995245

[132] Chen X,Zhou H.Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment..Cancer Discov2019;9:890-909 PMCID:PMC6606342

[133] Hanada M,Aiello A,Reed JC.Bcl-2 gene hypomethylation and high-level expression in b-cell chronic lymphocytic leukemia..Blood1993;82:1820-8

[134] Calin GA,Shimizu M.Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia..Proc Natl Acad Sci U S A2002;99:15524-9 PMCID:PMC137750

[135] Cimmino A,Fabbri M.miR-15 and miR-16 induce apoptosis by targeting BCL2..Proc Natl Acad Sci U S A2005;102:13944-9 PMCID:PMC1236577

[136] Anderson MA,Seymour JF.The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism..Blood2016;127:3215-24 PMCID:PMC4920022

[137] Huemer F,Jansko B.Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM..Eur J Haematol2019;102:437-41 PMCID:PMC6849823

[138] Konopleva M,Potluri J.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia..Cancer Discov2016;6:1106-17 PMCID:PMC5436271

[139] Tausch E,Dolnik A.Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia..Haematologica2019;104:e434-7 PMCID:PMC6717583

[140] Birkinshaw RW,Luo CS.Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations..Nat Commun2019;10:2385 PMCID:PMC6547681

[141] Blombery P,Gong JN.Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia..Cancer Discov2019;9:342-53

[142] Anderson MA,Lew TE.Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax..Blood2017;129:3362-70

[143] Tessoulin B,Gomez-Bougie P.BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker..Front Oncol2018;8:645 PMCID:PMC6330761

[144] Thijssen R,Weller K.Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors..Haematologica2015;100:e302-6 PMCID:PMC5004430

[145] Guièze R,Rosebrock D.Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies..Cancer Cell2019;36:369-84.e13 PMCID:PMC6801112

[146] Choudhary GS,Mazumder S.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies..Cell Death Dis2015;6:e1593 PMCID:PMC4669737

[147] Hollands C.Strychnine poisoning..Vet Rec1989;124:473

[148] Mazumder S,Al-Harbi S.Mcl-1 phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells..Cancer Res2012;72:3069-79 PMCID:PMC3377792

[149] Luedtke DA,Pan Y.Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells..Signal Transduct Target Ther2017;2:17012 PMCID:PMC5661618

[150] Niu X,Ma J.Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells..Clin Cancer Res2016;22:4440-51 PMCID:PMC5010519

[151] Lin KH,Xie A.Targeting MCL-1/BCL-XL forestalls the acquisition of Resistance to ABT-199 in acute myeloid leukemia..Sci Rep2016;6:27696 PMCID:PMC4901329

[152] Li Z,Look AT.The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells..Leukemia2019;33:262-6 PMCID:PMC6327051

[153] Weiss J,Herling CD,Hallek M.Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)..Haematologica2019;104:e540 PMCID:PMC6821598

[154] Beà S,Navarro A.Landscape of somatic mutations and clonal evolution in mantle cell lymphoma..Proc Natl Acad Sci U S A2013;110:18250-5 PMCID:PMC3831489

[155] Nechiporuk T,Nikolova O.The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells..Cancer Discov2019;9:910-25 PMCID:PMC6606338

[156] Sharon D,Mirali S.Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response..Sci Transl Med2019;11:eaax2863

[157] Jin S,Purkal JJ.5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis..Clin Cancer Res2020;26:3371-83

[158] Zhao S,Navsaria L.Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients..Am J Hematol2020;95:623-9

[159] Chyla B,Doyle K.Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia..Am J Hematol2018;E202-5 PMCID:PMC6120451

[160] Kim E,Liang Y.SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on Exon recognition..Cancer Cell2015;27:617-30 PMCID:PMC4429920

[161] Bogenberger JM,Pierceall WE.BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies..Leukemia2014;28:1657-65 PMCID:PMC4131248

[162] Pan R,Benito JM.Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia..Cancer Discov2014;4:362-75 PMCID:PMC3975047

[163] Bogenberger JM,Hansen N.Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies..Leuk Lymphoma2015;56:226-9 PMCID:PMC4331188

[164] Tsao T,Kornblau S.Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells..Ann Hematol2012;91:1861-70 PMCID:PMC3750747

[165] Pollyea DA,Jones CL.Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia..Nat Med2018;24:1859-66 PMCID:PMC7001730

[166] Jilg S,Kauschinger J.Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose..Exp Hematol Oncol2019;8:9 PMCID:PMC6469098

[167] Pei S,Gustafson A.Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia..Cancer Discov2020;10:536-51 PMCID:PMC7124979

[168] DiNardo CD,Quaglieri A.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML..Blood2020;135:791-803 PMCID:PMC7068032

[169] Maiti A,Cortes JE.Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens..Haematologica2020;

[170] Pievani A,Tomasoni C,Serafini M.Location first: targeting acute myeloid leukemia within its niche..J Clin Med2020;9:1513 PMCID:PMC7290711

[171] Jacamo R,Wang Z.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance..Blood2014;123:2691-702 PMCID:PMC3999754

[172] Matsunaga T,Sato T.Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia..Nat Med2003;9:1158-65

[173] Knight T,Taub JW.Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia..Cancer Manag Res2019;11:3197-213 PMCID:PMC6499443